Clinical Trial

Metaphylaxis of Infected Kidney Stones After Percutaneous Nephrolithotripsy

Study acronym: DIOX-PCNL
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 11, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Kidney stone recurrence, particularly infection-related stones, remains a significant clinical problem after percutaneous nephrolithotripsy (PCNL). Bacterial colonization and persistent infection are recognized contributors to stone recurrence. This study evaluates the effectiveness of intrarenal dioxidine instillation as a metaphylactic measure to reduce recurrence of infection-related kidney stones following PCNL. Patients undergoing PCNL will receive standard treatment, with or without adjunctive intrarenal dioxidine administration. The study aims to assess whether this approach reduces stone recurrence and infection-related complications.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-30.
Trial Details
NCT Number NCT07393711
Lead Sponsor West Kazakhstan Marat Ospanov Medical University
Conditions Kidney Calculi, Nephrolithiasis, Urinary Tract Infections
Enrollment 95 participants
Start Date 2026-03-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-11